NextGen Precision Health & EFCC Cancer Science Seminar - August 18, 2022
For questions about this event, please reach out to Veronica Lemme firstname.lastname@example.org
"Bruton’s Tyrosine Kinase/Inducible T-cell Kinase Inhibition in Graft-Versus-Host Disease"
Presented by: Gerhard Hildebrandt, MD, Director of Ellis Fischel Cancer Center
Date: Thursday, August 18, 2022, 4:30-5:30 p.m.
Location: Tom and Linda Atkins Family Seminar Room, Roy Blunt NextGen Precision Health building
*This event will have a Zoom option for those unable to attend in person.
In this presentation, Dr. Hildebrandt will describe how Differential Inhibition of Tec Kinases is beneficial in ameliorating Murine Sclerodermatous Chronic Graft-Versus-Host Disease. Graft-versus-host disease (GVHD) is a major factor limiting the widespread use of potentially curative allogeneic hematopoietic stem cell transplant (allo-HSCT). Chronic GVHD is characterized by activation of alloreactive donor immune cells, especially B- and T-cells, leading to tissue damage and pathogenic fibrosis. Additionally, Dr. Hildebrandt will share the overall direction of research for Ellis Fischel Cancer Center.
Dr. Hildebrandt earned a medical degree from the Johannes Gutenberg University of Mainz Medical School, Germany. Upon completing his doctoral research thesis, he was awarded the "doctor medicinae" with magna cum laude. He completed a residency in Internal Medicine and a Hematology and Oncology fellowship at the University of Regensburg, Germany, and became Bone Marrow Transplant and Hematologic Malignancies Attending at the University of Regensburg. In 2009, he was awarded the "Habilitation", the highest academic qualification a scholar can achieve by own pursuit in Germany.
After moving to the United States, he was a faculty member at the Louisiana State University in Shreveport and at the University of Utah. He was the director of the bone marrow transplant program at LSUHSC Shreveport and director of the Utah Blood and Marrow Transplant program at the Huntsman Cancer Institute/University of Utah before moving to Kentucky. Dr. Hildebrandt is currently serving as Director of Ellis Fischel Cancer Center and Chief of the Division of Hematology & Medical Oncology along with Professor of Clinical Medicine at University of Missouri.